Skip to main content
Feedback
Home

Professional Education

Learn.Share.Advance

Secondary Menu

  • Overview
  • Contact
  • Blog
  • EN
  • FR
  • EN
  • FR

Main menu

  • Transfusion
  • Organs and Tissues

Secondary Menu Mobile

  • Overview
  • Contact
  • Blog

Main navigation

  • Virtual tour
  • Events
      • Past events
  • Courses
      • LearnTransfusion series
      • AFC-diploma program in transfusion medicine
      • Genomics Transfusion Rounds
      • Sickle cell disease education program for health-care professionals
      • BloodTechNet educational resources
      • KnowledgeInfusion
      • Transfusion Camp
        • Medical Residents Transfusion Camp 2024-2025
        • Pediatric Transfusion Camp 2024-2025
        • Nurse Practitioners Transfusion Camp 2024 - 2025
        • Rwanda Transfusion Camp 2024 Staff
        • Rwanda Transfusion Camp 2024 trainees
        • United Kingdom Transfusion Camp 2024-2025
      • Other courses and learning resources
  • Clinical guide
      • Chapter 1 - Vein to vein: A summary of the blood system in Canada
      • Chapter 2 - Blood components
      • Chapter 3 - Albumin
      • Chapter 4 - Immunoglobulin products
      • Chapter 5 - Concentrates for hemostatic disorders and hereditary angioedema
      • Chapter 6 - Donor selection, donor testing and pathogen reduction
      • Chapter 7 - Fractionated blood products and associated pathogen safety
      • Chapter 8 - Pre-transfusion testing
      • Chapter 9 - Blood administration
      • Chapter 10 - Transfusion reactions
      • Chapter 11 - Massive hemorrhage and emergency transfusion
      • Chapter 12 - Hemolytic disease of the fetus and newborn and perinatal immune thrombocytopenia
      • Chapter 13 - Neonatal and pediatric transfusion
      • Chapter 14 - Therapeutic apheresis
      • Chapter 15 - Irradiated, washed and CMV seronegative blood components
      • Chapter 16 - Preoperative autologous donation
      • Chapter 17 - Hemostatic disorders and hereditary angioedema
      • Chapter 18 - Platelet transfusion, alloimmunization and management of platelet refractoriness
      • Chapter 19 - Pathogen-reduced platelets
      • Chapter 20 - Granulocyte transfusion therapy
  • Best practices
      • Breakthroughs in blood: Advancing practice through research
      • Blood utilization best practices
        • Blood System Inventory Management Best Practices Guide
        • Platelet clinical best practices
      • Uniform labelling
      • International Collaboration for Transfusion Medicine Guidelines (ICTMG)
      • Risk-based decision-making framework
      • Informed consent for blood transfusion
      • Red cell antigen genotyping reports
        • Red cell antigen genotyping report: A quick glance
        • Interpreting the red cell antigen genotyping report
      • Serological best practices
        • ABO subgroups
        • Diego system: anti-Dia
        • Diego system: anti-Wra
        • Kell System: Anti-Kpa
        • Kell system: anti-Jsa
        • Lewis system: anti-Lewis
        • Lutheran system: anti-Lua
        • MNS system: anti-M
        • Rh System: Anti-V
        • Rh system: anti-Cw
        • Whole blood donors with antibodies
      • Testing and management of fetal and neonatal alloimmune thrombocytopenia
      • Visual Inspection Tool
        • Red blood cells
          • Red blood cells: Bacterial contamination
          • Red blood cells: Hemolysis
          • Red blood cells: Lipemia
          • Red blood cells: Particulate matter
        • Platelets
          • Platelets: Bacterial contamination
          • Platelets: Bubbles
          • Platelets: Icterus
          • Platelets: Lipemia
          • Platelets: Other causes of discolouration
          • Platelets: Particulate matter
          • Platelets: Red blood cell contamination
        • Plasma
          • Plasma: Bacterial contamination
          • Plasma: Icterus
          • Plasma: Lipemia
          • Plasma: Other causes of discolouration
          • Plasma: Particulate matter
          • Plasma: Red blood cell contamination
        • Cryoprecipitate
          • Cryoprecipitate: Bacterial contamination
          • Cryoprecipitate: Icterus
          • Cryoprecipitate: Other causes of discolouration
          • Cryoprecipitate: Particulate matter
  • Publications
      • Paying it forward: Why we need YOU to give blood
      • National plan for the management of shortages of labile blood components
      • Phenotype matching and storage age of blood for sickle cell patients: A review and recommendations for transfusion practice
      • Anaphylactic transfusion reactions and IgA deficiency
      • Transfusion-related acute lung injury (TRALI)
      • Emergency framework for rationing of blood for massively bleeding patients during a red phase blood shortage
      • Blood bag spiking procedure
      • Platelet product quality remains high after seven days of storage
      • A survey of Canadian MLTs’ views on continuing education in transfusion science
      • A Guide to Reporting Adverse Transfusion Reactions
      • Alternative methods of blood donor skin disinfection
      • Blood: the basics
      • COVID-19
        • COVID-19 FAQ: Information for health professionals on safety of transfused blood collected from COVID-19-vaccinated donors
        • COVID-19: FAQ for health professionals working with blood products
        • FAQ: SARS-CoV-2 antibodies in immunoglobulin products
      • Exploring the frontiers of IVIG-associated hemolysis
      • FAQ: Canadian Blood Services platelet bacterial screening
      • FAQ: Delisting of directed donations at Canadian Blood Services
      • FAQ: Donor high titre isohemagglutinin (anti-A/anti-B) testing at Canadian Blood Services
      • FAQ: Information for health professionals on apheresis platelet psoralen-treated (APPT) and untreated apheresis platelet in PAS-E
      • FAQ: Information for health professionals on pathogen-reduced platelets
      • FAQ: Information for health professionals ordering granulocyte concentrates
      • FAQ: Solvent detergent (S/D) treated plasma (Octaplasma)
        • Octaplasma: One-page clinical summary
      • FAQ: Whole blood, leukocytes reduced, at Canadian Blood Services
      • Impact of COVID-19 on blood donation in Canada
      • Solvent detergent (S/D) treated plasma (Octaplasma)
      • Striking the balance: protecting data privacy in research
      • Summary of adverse transfusion reactions 2019-2024
      • Surveillance report
      • The importance of iron for whole blood donors: a Canadian perspective
  • Links
      • Canadian Society for Transfusion Medicine (CSTM)
      • National Advisory Committee on Blood and Blood Products
      • Provincial blood coordinating offices
      • Reference standards
      • Textbooks
      • Transfusionnews.com
      • Other links

Guide de la pratique transfusionnelle - Questions et commentaires

  2. Transfusion
  4. Clinical guide

© 2025 Canadian Blood Services. All rights reserved.

  • blood.ca
  • Contact us
  • Privacy policy
  • Legal